A Multinational, Open-label Study to Investigate Efficacy and Safety of Denecimig (Mim8) in Adults With Acquired Haemophilia A

Novo Nordisk A/S

Summary

The purpose of this study is to find out if denecimig is safe and effective for treating people who have acquired haemophilia A. Participants will be in this study for up to around 1 year and 5 months (73 week).

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female participants (sex assigned at birth, inclusive of all gender identities) newly diagnosed with acquired haemophilia A (AHA) prior to signing the informed consent form, with AHA diagnosis (FVIII activity lesser than (\<) 50 percentage (%) and FVIII inhibitors greater than (\>) 0.6 Bethesda units \[BU\]) confirmed at screening. * Treatment-requiring…

Locations (83)

University of Iowa_Iowa City
Iowa City, Iowa
Tulane University School of Medicine
Metairie, Louisiana
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
University of North Carolina
Chapel Hill, North Carolina

Summary

Eligibility

Interventions

Locations (83)